The ANSTO Nuclear Medicine (ANM) project encompasses the delivery of a world class nuclear medicine production facility located at ANSTO’s Lucas Heights campus in Sydney. The primary function of this facility revolves around the pharmaceutical production of Molybdenum-99 (Mo-99). Mo-99, which decays to Technitium-99, is used in around 80 percent of diagnostic nuclear medicine procedures worldwide for the diagnosis and treatment of heart, lung and muscular skeletal conditions, as well as a variety of cancers.
Nuclear Pharmaceutical Production
4,250 sq. m
ANSTO, Lucas Heights Campus, NSW